| Company/Division name | The U.S. Department of Health and Human Services |
| Parent company | Advin Biotech Inc |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Capital investment ($): | 4.5 |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | COVID-19 test |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Government Incentives, COVID-19 |
| Government Incentive dollar amount: | Biden-Harris administration investing $600 million |
